Book a Demo
Aman Chauhan
Gray shield icon
Is this you?
Claim your profile.

Aman Chauhan

Analyst

AS SEEN ON
OncLive

Preston's Summary

Aman Chauhan is an Analyst at various esteemed publications including India Fantasy, Electric Vehicle Info, and Sportskeeda. With a focus on medicine and healthcare, Aman covers critical topics such as oncology, endocrinology, immunotherapy, and palliative care, contributing to a deeper understanding of diagnostics and treatment advancements. His work has been featured in notable outlets like the Journal of Sustainable Tourism, MDPI, and OncLive.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Coverage Attributes:

Beta
Informative: 53 %
Data Driven: 41 %
Cites Data: 2 %
Events: 2 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Oncology
  • Endocrinology
  • Immunotherapy
  • Radiation Oncology
  • Pancreatic Cancer Research
  • Gene Therapy
  • Hematology
  • Palliative Care

Pitching Insights

Aman Chauhan's coverage is exclusively focused on event coverage within the realm of sports, specifically cricket and the T20 World Cup 2024. If you have insights or commentary related to specific cricket matches, player performance analyses, pitch conditions, or Dream11 predictions for ongoing tournaments, he would likely be receptive to your pitches.

Given his focus on match-specific content such as player battles and pitch reports, Aman may particularly appreciate expert analysis that adds depth and context to individual matchups during the T20 World Cup 2024.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Aislinn Antrim

Aislinn Antrim

Managing Editor
Publications
Pharmacy Times
Most recent topics
Not enough data
Liza Laws

Liza Laws

*******ws@******om
Publications
discover-pharma.com
Most recent topics
Not enough data
John Pinching

John Pinching

Editor
**********ing@************com
Publications
PharmaTimes Media Ltd
Most recent topics
Not enough data
Mary Caffrey

Mary Caffrey

Executive Editor, The American Journal of Managed Care
******ey@******om
Publications
AJMC - The American Journal of Managed Care
Most recent topics
Not enough data
Mark Leiser

Mark Leiser

Content Strategist
******r@********om
Publications
Healio
Most recent topics
Not enough data
Sabrina Serani

Sabrina Serani

Senior Editor
Publications
Targeted Oncology, Cancer Network, CURE Media Group
Most recent topics
Not enough data

Articles

OncLive

Sequencing of Systemic NETS Treatments

Sequencing of Systemic NETS Treatments

By: Andrew E. Hendifar, Aman Chauhan, Junaid Arshad, Namrata (Neena) Vijayvergia, Shagufta Shaheen

Experts discuss advanced treatment options for neuroendocrine tumors, highlighting PRRT, mTOR inhibitors, and emerging therapies for improved patient outcomes.

OncLive

Patient with NETS Post PRRT in Second-Line

Patient with NETS Post PRRT in Second-Line

By: Junaid Arshad, Andrew E. Hendifar, Namrata Neena, Shagufta Shaheen, Aman Chauhan

Experts discuss treatment options for a young patient with pancreatic neuroendocrine tumor and liver metastases, focusing on targeted therapies.

OncLive

Phase I data from the DARE7 trial evaluating obrixtamig, a DLL3/CD3 T-cell engager, in combination with platinum-based chemotherapy plus etoposide as first-line therapy for DLL3-positive neuroendocrine carcinomas

Phase I data from the DARE7 trial evaluating obrixtamig, a DLL3/CD3 T-cell engager, in combination with platinum-based chemotherapy plus etoposide as first-line therapy for DLL3-positive neuroendocrine carcinomas

By: Aman Chauhan

Obrixtamig in combination with platinum-based chemotherapy demonstrated encouraging clinical activity in patients with DLL3-positive neuroendocrine carcinomas, with high response rates and durable disease control. The regimen showed a manageable safety profile, with adverse events consistent with its mechanism and no unexpected toxicities. These findings support further development of this combination as a potential first-line treatment option.

© 2026 Intelligent Relations